RBC Capital analyst Ryan Halsted resumed coverage of Phreesia (PHR) with an Outperform rating and $26 price target Phreesia is positioned to accelerate growth and reach target margins following its pivot to profitability, leveraging its patient intake platform across 4,400 physicians to monetize network breadth and capture healthcare utilization economics, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR: